Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination

被引:140
作者
Trotter, CL [1 ]
Gay, NJ [1 ]
Edmunds, WJ [1 ]
机构
[1] Hlth Protect Agcy, Ctr Infect, Modelling & Econ Unit, London NW9 5EQ, England
关键词
disease transmission; immunity; herd; meningitis; meningococcal; serogroup C; meningococcal vaccines; models; theoretical; vaccination; vaccines; conjugate;
D O I
10.1093/aje/kwi160
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Much interest has surrounded the use of conjugate vaccines in recent years, with the development of vaccines against disease caused by Haemophilus influenzae type b, Neisseria meningitidis, and Streptococcus pneumoniae. These vaccines offer the potential for safe and effective disease control, but some questions remain, particularly regarding the duration and mechanisms of protection and the longer-term impact of vaccination on carriage. In this paper, the authors use data on immunization with serogroup C meningococcal conjugate vaccines in England and Wales to develop and apply a mathematical model to investigate the direct and indirect (herd immunity) effects of a conjugate vaccine program. A realistic, age-structured, dynamic model was developed and parameterized and was fitted to epidemiologic data from England and Wales. The effects of a range of vaccine strategies, including hypothetical scenarios, were investigated. The basic reproduction number was estimated to be 1.36. Catch-up vaccination targeting teenagers generated substantial herd immunity and was important in controlling disease rapidly. The results were sensitive to changes in the assumptions regarding the method of vaccine action, particularly duration of protection and efficacy of vaccination against carriage acquisition. This model can be used to help predict the potential impact of vaccine strategies both in the United Kingdom and elsewhere.
引用
收藏
页码:89 / 100
页数:12
相关论文
共 30 条
[1]  
ANDERSON R M, 1991
[2]   EFFECT OF OUTER-MEMBRANE VESICLE VACCINE AGAINST GROUP-B MENINGOCOCCAL DISEASE IN NORWAY [J].
BJUNE, G ;
HOIBY, EA ;
GRONNESBY, JK ;
ARNESEN, O ;
HOLSTFREDRIKSEN, J ;
HALSTENSEN, A ;
HOLTEN, E ;
LINDBAK, AK ;
NOKLEBY, H ;
ROSENQVIST, E ;
SOLBERG, LK ;
CLOSS, O ;
ENG, J ;
FROHOLM, LO ;
LYSTAD, A ;
BAKKETEIG, LS ;
HAREIDE, B .
LANCET, 1991, 338 (8775) :1093-1096
[3]   Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom [J].
Borrow, R ;
Goldblatt, D ;
Andrews, N ;
Southern, J ;
Ashton, L ;
Deane, S ;
Morris, R ;
Cartwright, K ;
Miller, E .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (09) :1353-1357
[4]   EFFICACY, SAFETY, AND IMMUNOGENICITY OF A MENINGOCOCCAL GROUP-B (15-P1.3) OUTER-MEMBRANE PROTEIN VACCINE IN IQUIQUE, CHILE [J].
BOSLEGO, J ;
GARCIA, J ;
CRUZ, C ;
ZOLLINGER, W ;
BRANDT, B ;
RUIZ, S ;
MARTINEZ, M ;
ARTHUR, J ;
UNDERWOOD, P ;
SILVA, W ;
MORAN, E ;
HANKINS, W ;
GILLY, J ;
MAYS, J .
VACCINE, 1995, 13 (09) :821-829
[5]   Economic evaluation of vaccination programs: The impact of herd-immunity [J].
Brisson, M ;
Edmunds, WJ .
MEDICAL DECISION MAKING, 2003, 23 (01) :76-82
[6]  
Cartwright K., 1995, Meningococcal Disease, P115
[7]   THE STONEHOUSE SURVEY - NASOPHARYNGEAL CARRIAGE OF MENINGOCOCCI AND NEISSERIA-LACTAMICA [J].
CARTWRIGHT, KAV ;
STUART, JM ;
JONES, DM ;
NOAH, ND .
EPIDEMIOLOGY AND INFECTION, 1987, 99 (03) :591-601
[8]  
*CHIEF MED OFF CHI, 2002, EXT MEN C VACC 20 24
[9]   Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age [J].
de Kleijn, ED ;
de Groot, R ;
Labadie, J ;
Lafeber, AB ;
van den Dobbelsteen, G ;
van Alphen, L ;
van Dijken, H ;
Kuipers, B ;
van Omme, GW ;
Wala, M ;
Juttmann, R ;
Rümke, HC .
VACCINE, 2000, 18 (15) :1456-1466
[10]   METHODS FOR ESTIMATING THE DURATION OF BACTERIAL CARRIAGE [J].
DEWALS, P ;
BOUCKAERT, A .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1985, 14 (04) :628-634